Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danavorexton in healthy adult men with experimentally induced opioid-induced respiratory depression
NL-OMON52033Phase 1Active, not recruiting
- Sponsor
- Takeda
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of danavorexton in opioid-induced respiratory depression (OIRD) (2 arms), sponsored by Takeda. Primary endpoint: Treatment-emergent adverse events. Started Mar 2022; status: active, not recruiting.
02
Drugs
danavorexton
03
Conditions
opioid-induced respiratory depression (OIRD)
Beyond the preview
Go deeper on NL-OMON52033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52033.